Development and Clinical Evaluation of a Novel Hollow Cusp Fracture Reducer for Femoral Shaft and Patellar Fractures
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 142
- 试验地点
- 1
- 主要终点
- Surgical time
研究概览
简要总结
This study aimed to develop and clinically evaluate a novel hollow cusp fracture reducer for enhancing the precision and efficiency of closed reduction and internal fixation in patients with femoral shaft fractures and patellar fractures. A prospective randomized controlled trial was conducted at Hanzhong Central Hospital between January 2020 and January 2023. A total of 142 patients were randomly assigned to either the experimental group treated with the novel reduction device or the control group undergoing conventional manual reduction. Primary outcome measures included operative time, number of fluoroscopic images, and K-wire insertion success rate. Secondary outcomes consisted of intraoperative blood loss, length of hospital stay, fracture healing time, and postoperative complication rate. Compared with the conventional technique, the novel hollow cusp fracture reducer significantly shortened operative time and reduced the frequency of intraoperative fluoroscopy, while markedly improving the accuracy of K-wire placement. Fracture healing was also accelerated in the device group. Complication rates were comparable or lower in the experimental group. The novel hollow cusp fracture reducer is safe and effective. It improves the accuracy and efficiency of fracture reduction, lowers radiation exposure, and facilitates earlier postoperative recovery. This device demonstrates high clinical value for the minimally invasive treatment of femoral shaft and patellar fractures.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Other
入排标准
- 年龄范围
- 30 Years 至 60 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age < 60 years.
- •Acute traumatic femoral shaft fracture or patellar fracture (AO/OTA classification)
- •Underwent closed reduction and internal fixation within 7 days of injury
- •Complete clinical and radiological follow-up data.
排除标准
- •Pathological, infected, or tuberculous fracture.
- •Severe osteoporosis or metabolic bone disease.
- •Open fractures, multiple fractures, or severe combined injuries.
- •Severe cardiac, hepatic, renal, or hematological comorbidities.
- •Patients who declined participation.
结局指标
主要结局
Surgical time
时间窗: "From enrollment to the end of treatment at 6 weeks"
Intraoperative bleeding
时间窗: "From enrollment to the end of treatment at 6 weeks
Number of C arm fluoroscopies
时间窗: From enrollment to the end of treatment at 6 weeks
Needle insertion success
时间窗: From enrollment to the end of treatment at 6 weeks
Success
时间窗: From enrollment to the end of treatment at 6 weeks
Overall complication rate
时间窗: "From enrollment to the end of treatment at 6 weeks
次要结局
未报告次要终点
研究者
Yadong Zhang
Doctor
Hanzhong Central Hospital
